A Phase 3 Open Label Extension study of TAK-279 in patients with plaque psoriasis
Research type
Research Study
Full title
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis
IRAS ID
1010407
Contact name
Jessamyn Blau
Contact email
Sponsor organisation
Takeda Development Center Americas Inc.
Clinicaltrials.gov Identifier
Research summary
Psoriasis is a skin disease that causes a rash with itchy, scaly patches. Psoriasis is a common, long-term (chronic) disease with no cure. It can be painful, interfere with sleep and make it hard to concentrate. Plaque psoriasis is the most common form of psoriasis. Its symptoms are dry skin lesions, known as plaques, covered in scales. They normally appear on elbows, knees, scalp and lower back, but can appear anywhere on the body. The plaques can be itchy or sore, or both.
TAK-279 is an experimental drug that is being developed by Takeda Development Center Americas, Inc,. The active ingredient in TAK-279 targets a substance (protein) in the body that is used by the immune system. This substance has been shown to be important in psoriasis.
This is a phase 3, multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy in adults with moderate-to-severe plaque psoriasis. This 2-part study will include: Part A, which will include de novo participants who did not participate in either of the parent studies, TAK-279-3001 or TAK-279-3002, and Part B, which will include both participants who have completed Part A and participants who have successfully completed either of the parent studies.REC name
North East - Newcastle & North Tyneside 2 Research Ethics Committee
REC reference
24/NE/0189
Date of REC Opinion
23 Dec 2024
REC opinion
Further Information Favourable Opinion